Julia Espel, MD
Critical Care Medicine · Palos Park, ILNPI 1134456742
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 252 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by GSK at 34.7% of the total.
Across 252 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Electromed, Inc.$525
- AstraZeneca$391
- Boehringer Ingelheim$358
- Insmed, Inc.$297
- Jazz Pharmaceuticals Inc.$222
- plus $1K from 16 others
What the payments were for
- Food & beverage$4,705100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 116 | $1,632 |
| Electromed, Inc. | 12 | $525 |
| AstraZeneca | 24 | $391 |
| Boehringer Ingelheim | 16 | $358 |
| Insmed, Inc. | 14 | $297 |
| Jazz Pharmaceuticals Inc. | 7 | $222 |
| Sanofi | 9 | $188 |
| Novartis | 10 | $185 |
| Grifols USA, LLC | 6 | $128 |
| Philips North America LLC | 5 | $124 |
| Genentech USA, Inc. | 6 | $119 |
| AbbVie | 5 | $99 |
| Inogen, Inc. | 3 | $75 |
| Regeneron Healthcare Solutions, Inc. | 2 | $63 |
| Mylan Specialty L.p. | 3 | $61 |
| Merck | 4 | $61 |
| Sunovion Pharmaceuticals Inc. | 4 | $45 |
| Amgen | 2 | $40 |
| Advanced Respiratory, Inc | 1 | $29 |
| Baxter Healthcare | 1 | $27 |
| Vapotherm Inc | 1 | $17 |
| Circassia Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SMARTVEST$395
How this compares
$4,705 in reported general payments places this provider in the 85th percentile of 281 critical care medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 181 | $140,026 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 134 | $86,639 |
| Dupixent SyringeDupilumab | 11 | $63,913 |
| Breo ElliptaFluticasone/Vilanterol | 94 | $46,155 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 57 | $28,564 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $22,574 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $8,063 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 228 | $6,363 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,924 |
| DuleraMometasone/Formoterol | 16 | $5,910 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 21 | $5,121 |
| Arnuity ElliptaFluticasone Furoate | 15 | $3,041 |
| Ventolin HfaAlbuterol Sulfate | 50 | $2,756 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $2,729 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,632 | $283,924443 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $358 | $34,48868 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $391 | $24,93647 claims |
| MerckDulera | $61 | $5,91016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 281 critical care medicine providers in Illinois.
Other critical care medicine in Palos Park
- Husam NayefPalos Park$24K
- Steven QuinnPalos Park$15K
- Sarah UsmaniPalos Park$7K
- Tabassum HanifPalos Park$6K
- Rafat MohammedPalos Park$5K
- Rohinee BeriPalos Park$4K
- Brian ReichardtO Fallon$892K
- Michael CutticaChicago$402K
- Daniel DillingMaywood$208K
- Israel RubinsteinChicago$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.